Analyst Price Targets — NGNE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 2, 2025 5:33 pm | — | H.C. Wainwright | $45.00 | $20.61 | TheFly | Neurogene looks 'deeply undervalued' after Taysha news, says H.C. Wainwright |
| April 14, 2025 11:53 am | Keith Tapper | BMO Capital | $16.00 | $10.89 | TheFly | Neurogene price target lowered to $16 from $45 at BMO Capital |
| March 25, 2025 11:01 am | Joel Beatty | Robert W. Baird | $38.00 | $14.20 | TheFly | Neurogene price target lowered to $38 from $46 at Baird |
| March 25, 2025 10:32 am | Mitchell Kapoor | H.C. Wainwright | $50.00 | $14.20 | TheFly | Neurogene price target lowered to $50 from $55 at H.C. Wainwright |
| November 20, 2024 9:53 pm | Paul Matteis | Stifel Nicolaus | $46.00 | $15.33 | StreetInsider | Neurogene (NGNE) PT Lowered to $46 at Stifel |
| November 19, 2024 9:02 pm | Keith Tapper | BMO Capital | $45.00 | $35.59 | StreetInsider | Neurogene (NGNE) PT Lowered to $45 at BMO Capital |
| November 12, 2024 2:09 pm | Keith Tapper | BMO Capital | $60.00 | $64.48 | StreetInsider | Neurogene (NGNE) PT Lowered to $60 at BMO Capital |
| November 12, 2024 2:04 pm | Paul Matteis | Stifel Nicolaus | $60.00 | $64.48 | StreetInsider | Neurogene (NGNE) PT Raised to $60 at Stifel |
| August 12, 2024 6:16 am | Mitchell Kapoor | H.C. Wainwright | $49.00 | $35.59 | TheFly | Neurogene price target lowered to $49 from $51 at H.C. Wainwright |
| June 26, 2024 4:04 pm | Keith Tapper | BMO Capital | $65.00 | $32.01 | StreetInsider | BMO Capital Starts Neurogene (NGNE) at Outperform |
Latest News for NGNE
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,450 shares of the Company's common stock to four new…
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts' earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the... Here Are Friday's Top Wall Street Analyst Research Calls: Block, Costco,…
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, an investigational gene therapy in late-stage clinical development as a potential best-in-class…
Shares of Neurogene Inc. (NASDAQ: NGNE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NGNE.
U.S. House Trading
No House trades found for NGNE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.